REFERENCES
1. Li Z, Chen J, Tang Y, Qin D, Tang Z. MASLD: an emerging factor in the pathophysiology and clinical management of ICC. Hepatoma Res. 2024;10:41.
2. Suzuki A, Henao R, Reed MC, et al. Lower hepatic CBS and PEMT expression in advanced NAFLD: inferencing strategies to lower homocysteine with a mathematical model. Metab Target Organ Damage. 2024;4:21.
3. Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. Metab Target Organ Damage. 2023;3:5.
4. Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023;20:487-503.
5. Gaull G, Sturman JA, Schaffner F. Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies. J Pediatr. 1974;84:381-90.
6. Torres L, García-Trevijano ER, Rodríguez JA, et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes: a new role for homocysteine in liver fibrosis. Biochim Biophys Acta. 1999;1455:12-22.
8. Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest. 2001;107:1263-73.
9. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-7.
10. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 1997;272:1935-42.
11. Gulsen M, Yesilova Z, Bagci S, et al. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2005;20:1448-55.
12. Ai Y, Sun Z, Peng C, Liu L, Xiao X, Li J. Homocysteine induces hepatic steatosis involving ER stress response in high methionine diet-fed mice. Nutrients. 2017;9:346.
13. Liang H, Xie X, Song X, et al. Orphan nuclear receptor NR4A1 suppresses hyperhomocysteinemia-induced hepatic steatosis in vitro and in vivo. FEBS Lett. 2019;593:1061-71.
14. Yan Y, Wu X, Wang P, et al. Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1α-ERO1α-dependent oxidative stress manner. Redox Biol. 2020;37:101742.
15. Tripathi M, Singh BK, Zhou J, et al. Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation. J Hepatol. 2022;77:1246-55.
16. Bagherieh M, Kheirollahi A, Zamani-Garmsiri F, Emamgholipour S, Meshkani R. Folic acid ameliorates palmitate-induced inflammation through decreasing homocysteine and inhibiting NF-κB pathway in HepG2 cells. Arch Physiol Biochem. 2023;129:893-900.
17. Wang Meng, Sun Yue, Yang Anning, et al. Effect of macrophage PDHA1 gene knockout on apoptosis of hepatocytes in mice with non-alcoholic fatty liver disease. Chin J Pathophysiol. 2023;39:123-30.
18. Xiang W, Yang Y, Weng L, et al. Hyperhomocysteinemia activates NLRP3 inflammasome to cause hepatic steatosis and insulin resistance via MDM2-mediated ubiquitination of HSF1. Int Immunopharmacol. 2023;118:110085.
19. Kim R, Nijhout HF, Reed MC. One-carbon metabolism during the menstrual cycle and pregnancy. PLoS Comput Biol. 2021;17:e1009708.
20. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:61-71.e15.
21. Cherubini A, Rosso C, Della Torre S. Sex-specific effects of PNPLA3 I148M. Liver Int. 2025;45:e16088.
22. Vilar-Gomez E, Pirola CJ, Sookoian S, et al. Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD. Am J Gastroenterol. 2021;116:994-1006.
23. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-69.
24. Núñez-Sánchez MÁ, Martínez-Sánchez MA, Sierra-Cruz M, et al. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease. J Pathol. 2024;264:101-11.
25. Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748-66.
26. Lu M, Wu Y, Xia M, Zhang Y. The role of metabolic reprogramming in liver cancer and its clinical perspectives. Front Oncol. 2024;14:1454161.
27. Mejia JC, Pasko J. Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg Clin North Am. 2020;100:535-49.
